Elekta AB (publ) (EKTAY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 76.25 means the share price is 76.25 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.95B is the value of all shares combined. Beta 1.09: the stock has moved about 9% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerElekta AB (publ) (EKTAY) trades at $5.12. Elekta AB (publ) is a Swedish medical technology company specializing in clinical solutions for cancer and brain disorders. Market cap: $1.95B, Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for EKTAY: EKTAY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EKTAY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
EKTAY: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Elekta AB (publ) (EKTAY) Healthcare & Pipeline Overview
Elekta AB (publ) provides radiotherapy and neurosurgery solutions, including advanced treatment delivery systems and software. With a global presence, Elekta focuses on precision radiation medicine, competing with companies offering similar technologies for cancer and brain disorder treatments, while navigating regulatory landscapes and technological advancements.
What Is the Investment Thesis for EKTAY?
Elekta AB (publ) presents a mixed investment case. The company's established position in radiation therapy and neurosurgery provides a stable revenue base. A dividend yield of 4.28% may attract income-focused investors. However, a negative profit margin of -0.2% and a high P/E ratio of -549.61 raise concerns about profitability. Growth catalysts include expanding the installed base of Elekta Unity MR-Linac systems and increasing software and service revenue. Potential risks include competition from established players and the capital-intensive nature of the medical technology industry. Investors should carefully weigh these factors before considering an investment in EKTAY.
Based on FMP financials and quantitative analysis
EKTAY Key Highlights
Market capitalization of $1.95B reflects Elekta's position in the medical technology sector.
- Dividend yield of 4.28% offers a potential income stream for investors.
- Gross margin of 37.5% indicates the profitability of Elekta's products and services before operating expenses.
- Beta of 1.09 suggests that EKTAY's stock price is slightly more volatile than the overall market.
- Negative profit margin of -0.2% signals challenges in achieving profitability.
Who Are EKTAY's Competitors?
EKTAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ARSUF Fagron N.V. | $27.50 | 0.00% | $2.02B | — |
| BOEUF Bonesupport Holding AB (publ) | $24.43 | 0.00% | $1.60B | — |
| EBOSY EBOS Group Limited | $26.00 | -0.38% | $1.33B | — |
| GENSF Genus plc | $31.07 | 0.00% | $2.06B | — |
| GRRMF Gerresheimer AG | $32.20 | 0.00% | $1.11B | — |
| XRAY DENTSPLY SIRONA Inc. | $10.37 | -1.21% | $2.08B | — |
| LMAT LeMaitre Vascular, Inc. | $79.10 | +0.38% | $1.81B | 905-pillar |
| NVCR Novocure | $15.35 | -1.79% | $1.79B | 305-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EKTAY's Key Strengths?
Established market position in radiation therapy and neurosurgery.
- Comprehensive product portfolio.
- Global presence and distribution network.
- Strong brand reputation.
What Are EKTAY's Weaknesses?
Negative profit margin.
- High P/E ratio.
- Dependence on capital equipment sales.
- Exposure to currency fluctuations.
What Could Drive EKTAY Stock Higher?
Continued adoption of Elekta Unity MR-Linac systems by cancer centers.
- Publication of clinical data demonstrating the efficacy of Elekta's solutions in treating cancer and brain disorders (expected Q4 2026).
- Expansion of Elekta's software and service offerings.
- Regulatory approvals for new products and technologies in key markets (expected H1 2027).
What Are the Key Risks for EKTAY?
Financial-distress signal — its Altman Z-Score of 1.25 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-6.4%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 76.25 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Competition from established players in the radiation therapy and neurosurgery markets.
- Technological obsolescence.
- Regulatory changes and compliance requirements.
- Economic downturns and healthcare spending constraints.
- Currency fluctuations.
What Are the Growth Opportunities for EKTAY?
- Expansion of Elekta Unity MR-Linac: Elekta Unity, an MR-Linac system, offers real-time imaging during radiation therapy. Increasing the installed base of Elekta Unity systems represents a significant growth opportunity. The market for MR-Linac systems is projected to reach $500 million by 2028. Elekta's competitive advantage lies in its integrated hardware and software platform.
- Growth in Software and Service Revenue: Elekta's software and service offerings, including MOSAIQ Plaza and Elekta Axis Cloud, provide recurring revenue streams. The market for oncology information systems is expected to reach $4 billion by 2027. Elekta's focus on integrated solutions and data analytics positions it for growth in this area.
- Emerging Markets Expansion: Expanding into emerging markets, such as China and India, offers significant growth potential. The demand for advanced cancer treatment solutions is increasing in these regions due to rising cancer incidence and improving healthcare infrastructure. Elekta's global presence and established distribution network provide a competitive advantage.
- Innovation in Neurosurgery: Elekta's Leksell Gamma Knife remains a leading solution for non-invasive brain surgery. Continued innovation in neurosurgery products and techniques can drive growth in this market. The market for neurosurgery devices is projected to reach $10 billion by 2029. Elekta's expertise in stereotactic neurosurgery positions it for continued success.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships and acquisitions can expand Elekta's product portfolio and market reach. Collaborating with other medical technology companies and research institutions can accelerate innovation and drive growth. Elekta's financial resources and industry expertise make it an attractive partner for potential acquisitions.
What Are EKTAY's Competitive Advantages?
- Established brand reputation in radiation therapy and neurosurgery.
- Proprietary technology and intellectual property.
- Extensive installed base of equipment.
- Strong relationships with key opinion leaders and medical professionals.
What Does EKTAY Do?
Elekta AB (publ) was founded in 1972 in Stockholm, Sweden, with the mission of improving patient outcomes through innovative medical technology. Initially focused on neurosurgery, the company pioneered the Leksell Gamma Knife, a device for non-invasive brain surgery. Over the years, Elekta expanded its portfolio to include radiation therapy systems, treatment planning software, and oncology information systems. Today, Elekta offers a comprehensive suite of solutions for cancer and brain disorder treatments, including the Versa HD linear accelerator, Elekta Unity MR-Linac, and MOSAIQ Plaza oncology information system. The company's products are used in hospitals and cancer centers worldwide, serving a global patient population. Elekta faces competition from other medical technology companies in the radiation oncology and neurosurgery markets.
What Products and Services Does EKTAY Offer?
- Develops and manufactures radiation therapy systems for cancer treatment.
- Offers neurosurgery products, including the Leksell Gamma Knife.
- Provides treatment planning software and oncology information systems.
- Delivers integrated hardware and software solutions for precision radiation medicine.
- Offers services, including installation, training, and support.
- Focuses on improving patient outcomes through innovative medical technology.
How Does EKTAY Make Money?
- Sells radiation therapy systems and neurosurgery products to hospitals and cancer centers.
- Generates revenue from software licenses and service contracts.
- Provides training and support services to customers.
- Offers financing solutions to facilitate equipment purchases.
What Industry Does EKTAY Operate In?
Elekta operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. The market for radiation therapy equipment is driven by the rising incidence of cancer and the growing adoption of precision radiation medicine. Elekta competes with companies like ARSUF (Accuray Incorporated) and BOEUF (Brainlab AG) in the radiation oncology and neurosurgery markets. The industry is also influenced by trends such as the integration of artificial intelligence and machine learning in treatment planning and delivery.
Who Are EKTAY's Key Customers?
- Hospitals and cancer centers
- Radiation oncologists
- Neurosurgeons
- Medical physicists
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 42 days ago
- ● No analyst coverage
- ● Reported in SEK, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 47 |
| 2026-08-27 | 47 |
| 2026-08-31 | 47 |
| 2026-09-04 | 47 |
| 2026-09-08 | 47 |
| 2026-09-11 | 47 |
What changed?
The score has stayed at 47.
Over the same 19 days the stock moved -13.2%.
Financial Health
Elekta AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.25 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Elekta AB (publ) stands at -6.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 11.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Elekta AB (publ) (EKTAY) Valuation Context
Valued at $1.95B, EKTAY is classified as a small-cap stock.
EKTAY Revenue & Earnings Trend
In Q1 FY2027, EKTAY generated $365.7M in top-line revenue, marking a sequential decrease of 25.8%. The company recorded net income of $27.3M, with diluted EPS of $0.07. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, EKTAY averaged $-0.02 in diluted EPS.
Company Profile
Elekta AB (publ) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Jakob Just-Bomholt. EKTAY has traded publicly since 2009.
EKTAY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Established market position in radiation therapy and neurosurgery.
- Comprehensive product portfolio.
- Global presence and distribution network.
- Strong brand reputation.
Bear Case
- Negative profit margin.
- High P/E ratio.
- Dependence on capital equipment sales.
- Exposure to currency fluctuations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $366M | $27M | $0.07 |
| Q4 FY2026 | $493M | -$90M | -$0.23 |
| Q3 FY2026 | $420M | $989,872.871 | $0.0026 |
| Q2 FY2026 | $420M | $24M | $0.06 |
Q1 FY2027 · filed 31 Jul 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from SEK at today's rate
EKTAY Latest News
-
FUJIFILM Americas Welcomes Michael J. Hartman as Vice President, General Counsel and Secretary
Yahoo! Finance: EKTAY News · Aug 27, 2026
-
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
seekingalpha.com · Aug 27, 2026
-
HCG begins patient treatment on Karnataka's first Elekta Unity MR-Linac, bringing MR-guided adaptive radiation therapy to the state
Yahoo! Finance: EKTAY News · Aug 18, 2026
-
These Healthcare Stocks Just Exploded In Momentum — Investors Are Taking Notice
benzinga · Dec 3, 2025
EKTAY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EKTAY.
Price Targets
Wall Street price target analysis for EKTAY.
EKTAY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EKTAY; grades run from A+ (80-100) to F (below 30).
Latest News
FUJIFILM Americas Welcomes Michael J. Hartman as Vice President, General Counsel and Secretary
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
HCG begins patient treatment on Karnataka's first Elekta Unity MR-Linac, bringing MR-guided adaptive radiation therapy to the state
These Healthcare Stocks Just Exploded In Momentum — Investors Are Taking Notice
Leadership: Jakob Just-Bomholt
CEO
Jakob Just-Bomholt serves as the CEO of Elekta AB (publ). His background includes extensive experience in the healthcare and technology sectors. Prior to joining Elekta, he held leadership positions at various multinational companies. His expertise spans strategic planning, business development, and operational management. He is responsible for leading Elekta's global operations and driving the company's growth strategy.
Track Record: Since assuming the role of CEO, Jakob Just-Bomholt has focused on driving innovation and expanding Elekta's market presence. Key milestones under his leadership include the continued development and commercialization of Elekta Unity MR-Linac and the expansion of the company's software and service offerings. He has also emphasized strategic partnerships and acquisitions to accelerate growth.
Elekta AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. EKTAY is an ADR, meaning that instead of directly owning shares of Elekta AB (publ) traded on the Stockholm exchange, U.S. investors own receipts representing those shares. This allows U.S. investors to trade in USD during U.S. market hours.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: EKTA
EKTAY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements. Trading on the OTC Other tier carries higher risks compared to trading on major exchanges like the NYSE or NASDAQ, due to less stringent regulations and potentially lower liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Established history and track record in the medical technology industry.
- Global presence and distribution network.
- Proprietary technology and intellectual property.
- Partnerships with reputable healthcare institutions.
- Presence of institutional investors.
EKTAY Healthcare Stock FAQ
Is EKTAY a good stock?
Stock Expert AI does not rate EKTAY buy, sell or hold. Elekta AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about EKTAY stock?
Analyst coverage of EKTAY stock is limited due to its OTC listing and ADR status. However, analysts generally recognize Elekta's established position in the radiation therapy and neurosurgery markets.
What are the key factors to evaluate for EKTAY?
Evaluate EKTAY on fundamentals, analyst consensus, and risk factors. P/E: 76.25x vs the S&P 500's ~20-25x. Elekta AB (publ) presents a mixed investment case. Not financial advice.
How frequently does EKTAY data refresh on this page?
EKTAY's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven EKTAY's recent stock price performance?
Elekta AB (publ) (EKTAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established market position in radiation therapy and neurosurgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EKTAY overvalued or undervalued right now?
Elekta AB (publ) (EKTAY) trades at 76.25x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EKTAY?
Yes, most major brokerages offer fractional shares of Elekta AB (publ) (EKTAY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EKTAY's earnings and financial reports?
Elekta AB (publ) (EKTAY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for EKTAY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited or unreliable.